Clinical Guidance on COVID-19 Vaccines for People with Solid Cancers

This guidance is intended for healthcare providers and is based on known evidence as of February 26, 2021.

This document relates to patients with solid tumours. For information on patients with hematological malignancies and those who have undergone hematopoietic stem cell transplant or CAR-T, please refer to other guidance document for that patient population. For general information, please refer to BCCDC Guidance and information on COVID-19 vaccines for providers.

Background and Context

As of December, 2020, Health Canada has given interim authorization to two vaccines, Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) for the prevention of COVID-19 disease caused by the SARS-CoV-2 virus.

The risk of mortality from COVID-19 disease appears to be higher in patients with cancer. However, patients with cancer were generally excluded from the COVID-19 vaccine trials if they were immunosuppressed by disease or treatment; although 3.9% of patients in the Pfizer-BioNTech vaccine trial had a malignancy.

Therefore, there are uncertainties as to whether COVID-19 vaccine is efficacious and safe in patients with cancer or undergoing therapy for their cancer (cytotoxic chemotherapy, endocrine therapy, targeted therapy, immunotherapy) and/or radiation therapy (external-beam, brachytherapy, or systemic), as well as the timing of immunization in relation to their cancer treatments.

Is the COVID-19 vaccines recommended for people with solid cancers?

B.C. Cancer recommends that COVID-19 vaccines not be withheld from individuals who meet the criteria for immunization per B.C.’s COVID-19 Immunization Plan, including those who have had COVID-19 infection.

This recommendation is based on the following:

- The National Advisory Committee on Immunization (NACI) recommends that immunosuppressed individuals be offered the vaccine if the benefits of vaccines outweigh the potential risks.
- Patients with cancer have an increased risk of death related to COVID-19 infection.
- The United Kingdom, the United States, France, and Australia have prioritized patients with cancer for COVID-19 immunizations.
Is the COVID-19 vaccine efficacious and safe in patients with cancer?

It is unknown if the currently available COVID-19 vaccines are efficacious in patients with cancer or undergoing systemic therapy. As with most vaccines, there is a potential for diminished immune response in individuals who are immunocompromised due to their disease or treatment.\(^1,2\) In addition, patients with active cancer or undergoing active cancer treatment seemed to be generally excluded from the COVID-19 vaccine trials. However, the Pfizer-BioNTech vaccine trial included 3.9% of patients with a malignancy.\(^6\)

The above noted COVID-19 vaccines are likely safe in patients with cancer or undergoing therapy for cancer as they are NOT live or attenuated. There are currently no known factors that would predispose these individuals to adverse events associated with the vaccines.\(^1,2\) At the time of authorization, there are no known serious warnings or precautions related to the vaccines in patients with cancer.\(^1,2\)

Are there any specific contraindications or exceptions for those within the cancer population?

Individuals should not receive the vaccines if they have a history of severe allergic reaction to a component of the vaccines\(^7\), including non-medicinal ingredients (see Table 1).\(^1,2\) Polysorbate (which is closely related to polyethylene glycol) is a common ingredient in multiple medications. Still, any clinical implications of potential cross-allergic reactions are unknown.\(^9\) Patients who have had a previous anaphylactic reaction to any medicine should be counselled about the risk of a reaction to the vaccine against the benefits of immunization. Health Canada continues to monitor any adverse events following immunization through their post-authorization surveillance process.

### Table 1. Non-medicinal ingredients\(^1,2,7\)

<table>
<thead>
<tr>
<th>Pfizer-BioNTech (BNT162b2)</th>
<th>Moderna (mRNA-1273)</th>
</tr>
</thead>
<tbody>
<tr>
<td>polyethylene glycol</td>
<td>polyethylene glycol</td>
</tr>
<tr>
<td>• ALC-0159 = 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide</td>
<td>• PEG2000 DMG 1,2-dimyristoylrglycerol, methoxy-polyethylene glycol</td>
</tr>
<tr>
<td>1,2-distearoyl-sn-glycero-3-phosphocholine</td>
<td>1,2-distearoyl-sn-glycero-3-phosphocholine</td>
</tr>
<tr>
<td>ALC-0315 = (4-hydroxybutyl) azanediyl bis(hexane-6,1-diyl)bis(2-hexyldecanoate)</td>
<td>Lipid SM-102</td>
</tr>
<tr>
<td>Dibasic sodium phosphate dihydrate</td>
<td>Acetic acid</td>
</tr>
<tr>
<td>Monobasic potassium phosphate</td>
<td>Sodium acetate</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>Tromethamine</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>Tromethamine hydrochloride</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>Cholesterol</td>
</tr>
<tr>
<td>Sucrose</td>
<td>Sucrose</td>
</tr>
<tr>
<td>Water for injection</td>
<td>Water for injection</td>
</tr>
</tbody>
</table>
Are there specific recommendations or considerations for safe and/or most effective administration?

There are no known studies regarding the timing of COVID-19 vaccine in relation to systemic therapy for cancer. Both vaccines are given as two injections with optimal protection assumed after the second dose of the Moderna vaccine and seven days after the second dose of the Pfizer-BioNTech vaccine for the general population. However, optimal protection and degree of protection, if any, in immunosuppressed individuals are currently unknown. The efficacy and duration of immunity after only one dose are unclear. Therefore, patients should be vaccinated with two injections as approved by Health Canada until further information is available.

Patients with cancer who are undergoing chemotherapy or other cancer treatments that affect the immune system will be offered vaccination according to B.C.’s COVID-19 Immunization Plan. In general, it is preferred that patients complete immunization before starting immunosuppressive therapy if possible, ideally at least 14 days after the second dose of either vaccine, Pfizer-BioNTech or Moderna.

*However, life-saving or prolonging therapy should not be delayed solely to complete immunization.*

Any other timing would require case-by-case assessment based on:

a. Risk of morbidity related to COVID-19 infection (including local incidence of the pandemic, cancer type, comorbidities that confer higher risk in the general population, etc.)

b. Cancer-related morbidity due to delay of active treatment, and

c. Suboptimal immunity protection due to insufficient time window between immunization and immunosuppressive therapy.

Recommendations for timing of COVID-19 immunization for adult patients (≥ 16 y.o) with solid malignancies commencing or already receiving treatment (outside the setting of bone marrow, hematopoietic stem cell transplant, or CAR-T) are listed in Table 2 below.

Special considerations for immunotherapy:

a. **Rituximab and other anti-CD20 monoclonal antibodies**
   Of note, patients receiving these agents may have a reduced immune response to vaccines in general that can extend to up to 6 months following treatment completion.

b. **Checkpoint inhibitors**
   Previous studies have not signalled an increased risk of complications of COVID-19 for patients on checkpoint inhibitors such as CTLA-4 inhibitors (e.g., ipilimumab), PD-1 inhibitors (e.g., nivolumab, pembrolizumab) and PD-L1 inhibitors (e.g., atezolizumab, durvalumab). There have been theoretical concerns of an enhanced immune reaction, particularly with CTLA-4 inhibitors. However, given the seriousness of COVID-19 infection, immunization is still recommended in this group even if a four-week window cannot be confirmed.
### Table 2. Suggested timing of vaccine injection and therapy for cancer

<table>
<thead>
<tr>
<th>Population</th>
<th>When should patients receive COVID-19 vaccine?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Immunosuppressive therapy</strong>*</td>
<td>Pfizer-BioNTech vaccine:</td>
</tr>
</tbody>
</table>
| - Before starting active treatment | - Two injections usually given 21-42 days apart<sup>10</sup>  
- Second injection at least two weeks before treatment*  
- First injection at least five weeks before treatment |
| | Moderna vaccine:  
- Two injections usually given 28-42 days apart<sup>11</sup>  
- Second injection at least two weeks before treatment*  
- First injection at least six weeks before treatment |
| **During cyclical treatment** | First injection in the week before next treatment as this is when counts are likely to be the highest.  
*Note: Avoid on same day as treatment* |
| **During maintenance or non-cyclical treatment (e.g., rituximab given every 3 months)** | At any time during treatment |
| **Endocrine therapy, targeted therapy (including PARP inhibitors)** | At any time during treatment |
| **Systemic corticosteroids†** | Ideally, systemic corticosteroids (at daily doses ≥ 20 mg prednisone or equivalent) should be avoided or completed at least 28 days before commencing the first vaccine dose when possible. If it is not possible, immunization should proceed. |
| **Patients due to start radiation therapy** | If immunization is pending, and it is possible to delay radiation therapy without compromising outcomes, radiation therapy should be postponed until anticipated immunity is achieved before commencing radiation |

*In general, it is preferred that patients complete immunization before starting immunosuppressive therapy, if possible, based on the timing of the treatments and the availability of vaccines at the time. However, life-saving or prolonging therapy should not be delayed solely to complete immunization.
<table>
<thead>
<tr>
<th>Population</th>
<th>When should patients receive COVID-19 vaccine?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients on radiation therapy‡</td>
<td>At any time during treatment while blood counts are near normal range, ideally as early in the course of radiation therapy as possible.</td>
</tr>
<tr>
<td>Patients who have completed a course of radiation therapy or during a regimen of cyclical radio-isotope therapy‡</td>
<td>Radiation therapy can suppress lymphocyte counts for months to years after treatment in a dose and volume dependent fashion. As it is not known what level of WBC counts would alter vaccine efficacy, there is no specific blood count level to target for vaccine delivery; however, if the radiation therapy regimen§ is expected to cause transient myelosuppression for up to eight weeks, immunization should start at least one week after the nadir of myelosuppression.</td>
</tr>
</tbody>
</table>

* Immunosuppressive therapy - including but not limited to cytotoxic chemotherapy, rituximab, obinutuzumab, alemtuzumab

‡ This recommendation does not relate to inhaled, nebulized, intra-articular, intrabursal or topical corticosteroids, which have no bearing on immunization timing.

‡ Injection should be given on the opposite side if unilateral radiation treatment is, or was, given to area of injection site

§ Myelosuppression on radiation therapy regimens varies with dose, fractionation, and patient factors but typically examples of suppressive regimens include hemi-body, total body, total marrow, whole abdominal, craniospinal, or total skin radiation.

References


Authors

Mario de Lemos, B.Sc (Pharm), M.Sc (Oncol), PharmD
Fatima Ladha, B.Sc, B.Sc (Pharm), PharmD
Dr. Scott Tyldesley, Medical Director, Radiation Oncology, BC Cancer
Dr. Helen Anderson, Medical Director, Provincial Systemic Program, BC Cancer
Dr. Stephen Chia, Tumour Group Council Chair, BC Cancer
Dr. Kim Nguyen Chi, Chief Medical Officer - BC Cancer
Dr. Allison Dawn Mah, Infectious Disease Specialist, Vancouver General Hospital
Dr. Gary Pansegrau, Senior Executive Director, clinical programs and policy – BC Cancer
Dr. Manish Sadarangani, Vaccine Evaluation Center – BCCH
Dr. Ghada Al-Rawahi, Medical Microbiologist Pathology, CWBC
Dr. Kerry Savage Medical Oncologist, BC Cancer – Vancouver
Dr. Monika Naus, BCCDC

Reviewers

BC Cancer Executive Medical Directors, BC Regional Cancer Centres
Medical Oncology and Radiation Oncology Department Heads
BC Cancer Tumour Group Leads, BC Cancer